ANXA2 and ovarian carcinoma: A combined panel of annexin A2 (ANXA2) and CA125 showed a sensitivity of 100%, a specificity of 63.6%, and an accuracy of 71.4% for distinguishing stage IA ovarian cancer from benign ovarian lesions, which was more accurate than the CA125 detection alone [95].